0001818382-22-000211.txt : 20221215 0001818382-22-000211.hdr.sgml : 20221215 20221215195158 ACCESSION NUMBER: 0001818382-22-000211 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221213 FILED AS OF DATE: 20221215 DATE AS OF CHANGE: 20221215 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Niklason Laura E CENTRAL INDEX KEY: 0001878075 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39532 FILM NUMBER: 221466217 MAIL ADDRESS: STREET 1: 35 WILSHIRE ROAD CITY: GREENWICH STATE: CT ZIP: 06831 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Humacyte, Inc. CENTRAL INDEX KEY: 0001818382 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 851763759 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2525 EAST NORTH CAROLINA HIGHWAY 54 CITY: DURHAM STATE: NC ZIP: 27713 BUSINESS PHONE: 919-313-9633 MAIL ADDRESS: STREET 1: 2525 EAST NORTH CAROLINA HIGHWAY 54 CITY: DURHAM STATE: NC ZIP: 27713 FORMER COMPANY: FORMER CONFORMED NAME: Alpha Healthcare Acquisition Corp. DATE OF NAME CHANGE: 20200716 4 1 wf-form4_167115188797248.xml FORM 4 X0306 4 2022-12-13 0 0001818382 Humacyte, Inc. HUMA 0001878075 Niklason Laura E 2525 EAST NORTH CAROLINA HIGHWAY 54 DURHAM NC 27713 1 1 1 0 President, CEO and Director Common Stock 2022-12-13 4 S 0 330000 2.84 D 18600004 I By Ayabudge LLC Common Stock 2022-12-14 4 S 0 276304 2.76 D 18323700 I By Ayabudge LLC Common Stock 2022-12-15 4 S 0 93426 2.63 D 18230274 I By Ayabudge LLC Common Stock 1160240 D Common Stock 510161 I By spouse The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for the purchasers to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Mr. Dougan, directly and indirectly, remains the largest shareholder of the Issuer. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly owned by Dr. Niklason were sold in these transactions. The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $2.77 to $3.06. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $2.75 to $2.87. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $2.60 to $2.80. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Laura E. Niklason by Dale A. Sander as Attorney-in-Fact 2022-12-15